bioMerieux’s Q3 sales came in below the consensus estimates. However, routine testing continued to witness sustained momentum with healthy growth across the board. While the overall growth was partially impacted by weaker respiratory sales, the 2023 guidance (still better vs. AV peers) was maintained. Overall, taking into account healthy routine testing market dynamics along with the new product launches being planned to leverage the high installed base and supported by a robust balance sheet, o ....
